Hepion pharmaceuticals to present at nash-tag 2024

Edison, n.j., jan. 03, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 nash-tag conference, which is being held january 4-6, 2024, in park city, utah.
HEPA Ratings Summary
HEPA Quant Ranking